A randomised phase III trial comparing cisplatin plus gemcitabine with gemcitabine alone for patients with advanced biliary tract cancer has provided evidence for a new standard treatment option for these patients. The therapeutic outcome (overall [more]
Non-small-cell lung cancers (NSCLC) covers a heterogeneous group of diseases, accounting for around 80% of all lung cancers, which were previously lumped together because there was no apparent reason to use different therapeutic approaches for [more]
Cisplatin-based chemoradiation has been shown to be superior to radiotherapy plus hydroxyurea for stage IB to III cervical cancer, conferring better survival rates withmodest long-term toxicity. Download full article